News | February 09, 2024
Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Submission to be reviewed under FDA real-time oncology review and Project Orbis
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The new campus has been designed as an employee-centred experience and ecosystem zone
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Subscribe To Our Newsletter & Stay Updated
